As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
REGULATORY
MHLW Panel Clears New Drugs from MSD, Pfizer, Amicus for Approval
Three new medicines gained the blessing of a key health ministry panel on June 4 that sets the stage for their Japanese regulatory approvals, including MSD’s sotatercept and Pfizer’s etrasimod. Sotatercept was recommended approval by the Pharmaceutical Affairs Council’s First…
To read the full story
Related Article
- Mochida’s Low-Dose Lialda to Hit Shelves in September
August 19, 2025
- Japan Approves MSD’s Airwin/Welireg, J&J Bispecific, and More
June 25, 2025
- Pfizer’s UC Drug, MSD’s PAH Therapy, and More Up for Panel Review on June 4
May 22, 2025
- MSD Files PAH Treatment Sotatercept in Japan
November 15, 2024
- Amvuttra Filed for ATTR-CM in Japan: Alnylam
November 12, 2024
- Aculys Pharma Files Diazepam Nasal Spray in Japan
September 3, 2024
- Tremfya Filed for Crohn’s Disease in Japan: J&J
August 13, 2024
- Takeda Seeks CIDP Nod for Immunoglobulin Hyqvia in Japan
August 9, 2024
- Mochida Files Pediatric Dosage of UC Drug Lialda in Japan
July 23, 2024
- Pfizer Seeks Japan Approval for Ulcerative Colitis Drug
July 1, 2024
- Mundipharma Files Anesthetic Med Anerem for New Indication in Japan
September 28, 2023
REGULATORY
- Chuikyo Discusses Lower Prices for Low-Novelty Drugs, PMP Criteria, Re-Pricing
November 20, 2025
- Chuikyo Split over How to Ease Negative Margins
November 20, 2025
- Providers Urging Possible Price Measures over Packaging Misalignment
November 20, 2025
- Providers Push to Expand 2% Buffer Zone in Drug Price Revisions as Costs Rise
November 20, 2025
- Japan Moves to Advance “G1” Price Cuts by 5 Years under Proposed LLP Overhaul
November 20, 2025
Japan is set to tighten reimbursement rules for regenerative medicine products granted conditional, time-limited approval, with Central Social Insurance Medical…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…